下一代癌症诊断市场－全球产业规模、份额、趋势、机会及预测（按技术、应用、癌症类型、地区和竞争格局划分，2021-2031年）

全球新一代癌症诊断市场预计将从 2025 年的 160.2 亿美元成长到 2031 年的 258.9 亿美元，复合年增长率为 8.33%。

这些先进的诊断系统利用先进的基因组学和蛋白​​质组学技术，包括高通量定序和液态生物检体，来检测对肿瘤患者管理至关重要的特定生物标记。推动市场扩张的关键因素是全球恶性肿瘤负担日益加重，这促使人们需要早期、准确的检测方法来支持个人化治疗策略。美国癌症协会的数据凸显了这种紧迫性，该协会估计，到2024年，美国将新增约2,001,140例癌症病例，这凸显了对可扩展诊断解决方案的迫切需求，这些解决方案能够推进精准肿瘤学的发展并改善患者预后。

儘管临床获益显而易见，但市场仍面临许多挑战，包括定序基础设施所需的大量资本投入以及高昂的检测营运成本。这些财务挑战限制了这些技术在成本敏感地区的广泛应用，而复杂的报销政策更令医疗服务提供者不确定性，加剧了这些挑战。因此，这些经济和监管方面的挑战使得新型诊断检测难以整合到标准治疗通讯协定中，限制了其应用，儘管这些检测具有提升癌症治疗水平的潜力。

市场驱动因素

次世代定序和液态生物检体技术的进步正在从根本上改变癌症诊断领域，实现高通量、非侵入性的肿瘤分析。特别是液态生物检体技术的创新，能够精准识别循环肿瘤DNA，为早期检测和持续病患监测提供了一种切实可行的替代方案，取代了传统的组织切片检查。这些技术的商业性成功体现在主要产业参与者不断增长的检测量上。例如，Guardant Health在2025年2月的财务报告中宣布，其年收入成长31%至7.39亿美元，主要得益于临床肿瘤检测量成长20%。同样，Exact Sciences在其2025年2月的报告中宣布，其2024年全年总收入为27.6亿美元，这表明市场对先进的筛检和诊断工具的需求强劲。

此外，基因组定序成本的下降是推动更广泛患者群体获得先进诊断技术的关键因素。儘管高成本历来限制了基因组分析的临床应用，但定序化学和平台效率的持续改进正在显着降低每GB数据的成本。如同2025年3月《前沿基因组学》（Front Line Genomics）杂誌的一篇报导所述，Illumina公司已证明，其最新平台可望将全基因组定序的成本降低至200美元。经济门槛的降低至关重要，它使医疗机构能够将全面的基因组分析纳入常规标准诊疗通讯协定，并加速精准肿瘤学在全球的普及。

市场挑战

建构定序基础设施所需的大量资本投入，加上高昂的检测营运成本，是限制全球下一代癌症诊断市场成长的主要障碍。这些资金需求限制了先进基因组技术的应用，使其主要局限于资金雄厚的医疗中心，实际上将小规模的医疗机构和经济欠发达地区排除在市场之外。这种经济上的排他性阻碍了可扩展诊断解决方案的广泛部署，缩小了潜在基本客群，并抑制了整体市场规模的成长。

此外，这些检测的高昂费用对患者和支付方都造成了沉重的经济负担，使报销流程复杂化，也难以将其纳入标准治疗方案。近期关于癌症治疗经济负担的统计数据也印证了这一经济负担：在2024年美国临床肿瘤学会（ASCO）年会上发表的一项分析显示，确诊癌症后六个月内，拥有私人保险的在职成年人的医疗总费用中位数为60,123美元。如此高昂的费用使得医疗系统难以将这些昂贵的诊断工具标准化，直接影响了市场满足全球日益增长的精准癌症治疗需求的能力。

市场趋势

人工智慧 (AI) 与精准分析的融合正在革新全球新一代癌症诊断市场，协助解读日益复杂的生物数据。随着诊断检测从单一生物标记检测发展到多模态态分析，人工智慧在关联基因组变异与临床结果以及识别传统方法往往忽略的细微预测特征方面变得至关重要。这种技术融合正在推动商业性成长，Tempus AI 截至 2025 年 2 月的财年业绩（营收 6.934 亿美元，年成长 30.4%）就印证了这一点。这一快速成长主要归功于该公司人工智慧驱动的精准医疗和数据解决方案的可扩展部署。

同时，伴随诊断联合开发伙伴关係的拓展正在加强诊断检测与标靶治疗选择之间的关联。製药公司和诊断设备製造商正日益建立策略联盟，共同开发新型药物的配套检测，尤其是在免疫肿瘤学和抗体药物复合体（ADC）领域，从而确保在诊疗现场对患者合格进行高度精准的判断。此类合作对于降低药物研发风险、加速监管核准至关重要，并为诊断设备领导企业创造可持续的收入来源。例如，安捷伦科技公司公布其诊断和基因组学部门2024年11月的年收入为16.5亿美元，凸显了儘管面临行业整体的挑战，市场对其病理诊断和伴随诊断产品组合的持续需求。

目录

第一章概述

第二章调查方法

第三章执行摘要

第四章：客户评价

第五章：全球下一代癌症诊断市场展望

• 市场规模及预测
  • 按金额
• 市占率及预测
  • 透过技术（次世代定序、qPCR 和多重 PCR、实验室晶片(LOAC) 和逆转录聚合酵素链锁反应(RT-PCR)、蛋白质微阵列、DNA 微阵列）
  • 依应用领域划分（生物标记开发、循环肿瘤细胞分析、蛋白质体学分析、表观遗传学分析、基因分析）
  • 癌症类型（肺癌、乳癌、结肠癌、子宫颈癌、其他）
  • 按地区
  • 按公司（2025 年）
• 市场地图

第六章：北美下一代癌症诊断市场展望

• 市场规模及预测
• 市占率及预测
• 北美洲：国家分析
  • 我们
  • 加拿大
  • 墨西哥

第七章：欧洲下一代癌症诊断市场展望

• 市场规模及预测
• 市占率及预测
• 欧洲：国家分析
  • 德国
  • 法国
  • 英国
  • 义大利
  • 西班牙

第八章：亚太地区下一代癌症诊断市场展望

• 市场规模及预测
• 市占率及预测
• 亚太地区：国家分析
  • 中国
  • 印度
  • 日本
  • 韩国
  • 澳洲

第九章：中东和非洲下一代癌症诊断市场展望

• 市场规模及预测
• 市占率及预测
• 中东和非洲：国家分析
  • 沙乌地阿拉伯
  • 阿拉伯聯合大公国
  • 南非

第十章：南美洲下一代癌症诊断市场展望

• 市场规模及预测
• 市占率及预测
• 南美洲：国家分析
  • 巴西
  • 哥伦比亚
  • 阿根廷

第十一章 市场动态

• 司机
• 任务

第十二章 市场趋势与发展

• 併购
• 产品发布
• 最新进展

第十三章：全球下一代癌症诊断市场：SWOT分析

第十四章 波特五力分析

• 产业竞争
• 新进入者的可能性
• 供应商电力
• 顾客权力
• 替代品的威胁

第十五章 竞争格局

• GE HealthCare
• Janssen Pharmaceuticals, Inc.
• Illumina, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips NV
• QIAGEN
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc

第十六章 策略建议

第十七章：关于研究公司及免责声明

The Global Next Generation Cancer Diagnostics Market is projected to expand from USD 16.02 Billion in 2025 to USD 25.89 Billion by 2031, registering a CAGR of 8.33%. These advanced diagnostic systems leverage sophisticated genomic and proteomic technologies, including high-throughput sequencing and liquid biopsies, to detect specific biomarkers essential for patient management in oncology. The primary catalyst for this market expansion is the escalating global burden of malignancies, which drives the need for early and precise detection methods to support personalized treatment strategies. This urgency is highlighted by data from the American Cancer Society, which estimated approximately 2,001,140 new cancer cases in the United States in 2024, reinforcing the critical demand for scalable diagnostic solutions that facilitate precision oncology and enhance patient outcomes.

Despite the evident clinical benefits, the market encounters significant obstacles regarding the heavy capital investment needed for sequencing infrastructure and the elevated operational costs of test execution. These financial hurdles restrict the widespread adoption of these technologies in cost-sensitive regions and are frequently exacerbated by complicated reimbursement policies that introduce uncertainty for healthcare providers. Consequently, these economic and regulatory barriers make it challenging to integrate novel diagnostic assays into standard care protocols, limiting their accessibility despite their potential to improve cancer care standards.

Market Driver

Technological advancements in next-generation sequencing and liquid biopsy are fundamentally transforming the cancer diagnostics sector by facilitating high-throughput, non-invasive tumor profiling. In particular, innovations in liquid biopsy allow for the accurate identification of circulating tumor DNA, providing a practical alternative to conventional tissue biopsies for early detection and ongoing patient monitoring. The commercial success of these technologies is reflected in the rising test volumes of major industry players; for instance, Guardant Health reported a 31% increase in full-year revenue to $739 million in its February 2025 financial results, driven largely by a 20% rise in clinical oncology test volumes. Similarly, Exact Sciences announced total revenue of $2.76 billion for the full year 2024 in its February 2025 report, demonstrating the robust market demand for advanced screening and diagnostic tools.

Additionally, the declining cost of genomic sequencing is acting as a vital catalyst for democratizing access to these advanced diagnostic capabilities across a wider patient population. Although high costs have historically limited the clinical implementation of genomic profiling, continuous improvements in sequencing chemistry and platform efficiency are significantly lowering the cost per gigabyte of data. As noted in a March 2025 article by Front Line Genomics, Illumina indicated that its latest platforms could potentially lower the cost of whole genome sequencing to $200. This reduction in financial barriers is crucial, as it enables healthcare providers to incorporate comprehensive genomic profiling into routine standard-of-care protocols, thereby accelerating the global adoption of precision oncology.

Market Challenge

The substantial capital investment necessary to establish sequencing infrastructure, combined with the high operational costs of test execution, poses a major barrier to the growth of the Global Next Generation Cancer Diagnostics Market. These financial demands limit the adoption of advanced genomic technologies primarily to well-funded medical centers, effectively excluding smaller healthcare facilities and economically constrained regions from participating in the market. This economic exclusivity hampers the broad deployment of scalable diagnostic solutions, narrowing the potential customer base and stalling the overall growth of market volume.

Moreover, the high price of these assays creates significant financial toxicity for both patients and payers, complicating the processes of reimbursement and integration into standard care. This financial strain is underscored by recent statistics on the economic burden of cancer treatment; an analysis presented at the 2024 American Society of Clinical Oncology annual meeting revealed that median total healthcare spending for working-age adults with private insurance was $60,123 in the six months following a diagnosis. Such prohibitive costs discourage healthcare systems from standardizing these expensive diagnostic tools, directly affecting the market's ability to satisfy the rising global demand for precision oncology.

Market Trends

The integration of artificial intelligence into precision analytics is revolutionizing the Global Next Generation Cancer Diagnostics Market by facilitating the interpretation of increasingly complex biological data. As diagnostic assays evolve from single-biomarker detection to multimodal profiling, AI is becoming indispensable for correlating genomic alterations with clinical outcomes and identifying subtle predictive signatures that traditional methods might miss. This convergence of technologies is driving commercial growth, as evidenced by Tempus AI, which reported a 30.4% year-over-year revenue increase to $693.4 million in its February 2025 financial results, a surge attributed largely to the scalable adoption of its AI-enabled precision medicine and data solutions.

Concurrently, the expansion of companion diagnostics co-development partnerships is strengthening the link between diagnostic testing and targeted therapeutic selection. Pharmaceutical and diagnostic companies are increasingly forming strategic alliances to develop assays alongside novel drugs, particularly for immuno-oncology and antibody-drug conjugates, ensuring that patient eligibility is determined with high specificity at the point of care. These collaborations are crucial for mitigating drug development risks and accelerating regulatory approvals, thereby creating resilient revenue streams for diagnostic leaders. For example, Agilent Technologies reported in November 2024 that its Diagnostics and Genomics Group generated $1.65 billion in annual revenue, highlighting the sustained market demand for its pathology and companion diagnostic portfolio despite broader industry headwinds.

Key Market Players

• GE HealthCare
• Janssen Pharmaceuticals, Inc.
• Illumina, Inc.
• Novartis AG
• F. Hoffmann-La Roche Ltd
• Koninklijke Philips N.V.
• QIAGEN
• Agilent Technologies, Inc.
• Abbott Laboratories Inc.
• Thermo Fisher Scientific Inc

Report Scope

In this report, the Global Next Generation Cancer Diagnostics Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Next Generation Cancer Diagnostics Market, By Technology

• Next-generation Sequencing
• qPCR & Multiplexing
• Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR)
• Protein Microarrays
• DNA Microarrays

Next Generation Cancer Diagnostics Market, By Application

• Biomarker Development
• CTC Analysis
• Proteomic Analysis
• Epigenetic Analysis
• Genetic Analysis

Next Generation Cancer Diagnostics Market, By Cancer Type

• Lung Cancer
• Breast Cancer
• Colorectal Cancer
• Cervical Cancer
• Others

Next Generation Cancer Diagnostics Market, By Region

• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Next Generation Cancer Diagnostics Market.

Available Customizations:

Global Next Generation Cancer Diagnostics Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

• 1.1. Market Definition
• 1.2. Scope of the Market
  • 1.2.1. Markets Covered
  • 1.2.2. Years Considered for Study
  • 1.2.3. Key Market Segmentations

2. Research Methodology

• 2.1. Objective of the Study
• 2.2. Baseline Methodology
• 2.3. Key Industry Partners
• 2.4. Major Association and Secondary Sources
• 2.5. Forecasting Methodology
• 2.6. Data Triangulation & Validation
• 2.7. Assumptions and Limitations

3. Executive Summary

• 3.1. Overview of the Market
• 3.2. Overview of Key Market Segmentations
• 3.3. Overview of Key Market Players
• 3.4. Overview of Key Regions/Countries
• 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Next Generation Cancer Diagnostics Market Outlook

• 5.1. Market Size & Forecast
  • 5.1.1. By Value
• 5.2. Market Share & Forecast
  • 5.2.1. By Technology (Next-generation Sequencing, qPCR & Multiplexing, Lab-on- a- chip (LOAC) & Reverse Transcriptase-PCR (RT-PCR), Protein Microarrays, DNA Microarrays)
  • 5.2.2. By Application (Biomarker Development, CTC Analysis, Proteomic Analysis, Epigenetic Analysis, Genetic Analysis)
  • 5.2.3. By Cancer Type (Lung Cancer, Breast Cancer, Colorectal Cancer, Cervical Cancer, Others)
  • 5.2.4. By Region
  • 5.2.5. By Company (2025)
• 5.3. Market Map

6. North America Next Generation Cancer Diagnostics Market Outlook

• 6.1. Market Size & Forecast
  • 6.1.1. By Value
• 6.2. Market Share & Forecast
  • 6.2.1. By Technology
  • 6.2.2. By Application
  • 6.2.3. By Cancer Type
  • 6.2.4. By Country
• 6.3. North America: Country Analysis
  • 6.3.1. United States Next Generation Cancer Diagnostics Market Outlook
    • 6.3.1.1. Market Size & Forecast
      • 6.3.1.1.1. By Value
    • 6.3.1.2. Market Share & Forecast
      • 6.3.1.2.1. By Technology
      • 6.3.1.2.2. By Application
      • 6.3.1.2.3. By Cancer Type
  • 6.3.2. Canada Next Generation Cancer Diagnostics Market Outlook
    • 6.3.2.1. Market Size & Forecast
      • 6.3.2.1.1. By Value
    • 6.3.2.2. Market Share & Forecast
      • 6.3.2.2.1. By Technology
      • 6.3.2.2.2. By Application
      • 6.3.2.2.3. By Cancer Type
  • 6.3.3. Mexico Next Generation Cancer Diagnostics Market Outlook
    • 6.3.3.1. Market Size & Forecast
      • 6.3.3.1.1. By Value
    • 6.3.3.2. Market Share & Forecast
      • 6.3.3.2.1. By Technology
      • 6.3.3.2.2. By Application
      • 6.3.3.2.3. By Cancer Type

7. Europe Next Generation Cancer Diagnostics Market Outlook

• 7.1. Market Size & Forecast
  • 7.1.1. By Value
• 7.2. Market Share & Forecast
  • 7.2.1. By Technology
  • 7.2.2. By Application
  • 7.2.3. By Cancer Type
  • 7.2.4. By Country
• 7.3. Europe: Country Analysis
  • 7.3.1. Germany Next Generation Cancer Diagnostics Market Outlook
    • 7.3.1.1. Market Size & Forecast
      • 7.3.1.1.1. By Value
    • 7.3.1.2. Market Share & Forecast
      • 7.3.1.2.1. By Technology
      • 7.3.1.2.2. By Application
      • 7.3.1.2.3. By Cancer Type
  • 7.3.2. France Next Generation Cancer Diagnostics Market Outlook
    • 7.3.2.1. Market Size & Forecast
      • 7.3.2.1.1. By Value
    • 7.3.2.2. Market Share & Forecast
      • 7.3.2.2.1. By Technology
      • 7.3.2.2.2. By Application
      • 7.3.2.2.3. By Cancer Type
  • 7.3.3. United Kingdom Next Generation Cancer Diagnostics Market Outlook
    • 7.3.3.1. Market Size & Forecast
      • 7.3.3.1.1. By Value
    • 7.3.3.2. Market Share & Forecast
      • 7.3.3.2.1. By Technology
      • 7.3.3.2.2. By Application
      • 7.3.3.2.3. By Cancer Type
  • 7.3.4. Italy Next Generation Cancer Diagnostics Market Outlook
    • 7.3.4.1. Market Size & Forecast
      • 7.3.4.1.1. By Value
    • 7.3.4.2. Market Share & Forecast
      • 7.3.4.2.1. By Technology
      • 7.3.4.2.2. By Application
      • 7.3.4.2.3. By Cancer Type
  • 7.3.5. Spain Next Generation Cancer Diagnostics Market Outlook
    • 7.3.5.1. Market Size & Forecast
      • 7.3.5.1.1. By Value
    • 7.3.5.2. Market Share & Forecast
      • 7.3.5.2.1. By Technology
      • 7.3.5.2.2. By Application
      • 7.3.5.2.3. By Cancer Type

8. Asia Pacific Next Generation Cancer Diagnostics Market Outlook

• 8.1. Market Size & Forecast
  • 8.1.1. By Value
• 8.2. Market Share & Forecast
  • 8.2.1. By Technology
  • 8.2.2. By Application
  • 8.2.3. By Cancer Type
  • 8.2.4. By Country
• 8.3. Asia Pacific: Country Analysis
  • 8.3.1. China Next Generation Cancer Diagnostics Market Outlook
    • 8.3.1.1. Market Size & Forecast
      • 8.3.1.1.1. By Value
    • 8.3.1.2. Market Share & Forecast
      • 8.3.1.2.1. By Technology
      • 8.3.1.2.2. By Application
      • 8.3.1.2.3. By Cancer Type
  • 8.3.2. India Next Generation Cancer Diagnostics Market Outlook
    • 8.3.2.1. Market Size & Forecast
      • 8.3.2.1.1. By Value
    • 8.3.2.2. Market Share & Forecast
      • 8.3.2.2.1. By Technology
      • 8.3.2.2.2. By Application
      • 8.3.2.2.3. By Cancer Type
  • 8.3.3. Japan Next Generation Cancer Diagnostics Market Outlook
    • 8.3.3.1. Market Size & Forecast
      • 8.3.3.1.1. By Value
    • 8.3.3.2. Market Share & Forecast
      • 8.3.3.2.1. By Technology
      • 8.3.3.2.2. By Application
      • 8.3.3.2.3. By Cancer Type
  • 8.3.4. South Korea Next Generation Cancer Diagnostics Market Outlook
    • 8.3.4.1. Market Size & Forecast
      • 8.3.4.1.1. By Value
    • 8.3.4.2. Market Share & Forecast
      • 8.3.4.2.1. By Technology
      • 8.3.4.2.2. By Application
      • 8.3.4.2.3. By Cancer Type
  • 8.3.5. Australia Next Generation Cancer Diagnostics Market Outlook
    • 8.3.5.1. Market Size & Forecast
      • 8.3.5.1.1. By Value
    • 8.3.5.2. Market Share & Forecast
      • 8.3.5.2.1. By Technology
      • 8.3.5.2.2. By Application
      • 8.3.5.2.3. By Cancer Type

9. Middle East & Africa Next Generation Cancer Diagnostics Market Outlook

• 9.1. Market Size & Forecast
  • 9.1.1. By Value
• 9.2. Market Share & Forecast
  • 9.2.1. By Technology
  • 9.2.2. By Application
  • 9.2.3. By Cancer Type
  • 9.2.4. By Country
• 9.3. Middle East & Africa: Country Analysis
  • 9.3.1. Saudi Arabia Next Generation Cancer Diagnostics Market Outlook
    • 9.3.1.1. Market Size & Forecast
      • 9.3.1.1.1. By Value
    • 9.3.1.2. Market Share & Forecast
      • 9.3.1.2.1. By Technology
      • 9.3.1.2.2. By Application
      • 9.3.1.2.3. By Cancer Type
  • 9.3.2. UAE Next Generation Cancer Diagnostics Market Outlook
    • 9.3.2.1. Market Size & Forecast
      • 9.3.2.1.1. By Value
    • 9.3.2.2. Market Share & Forecast
      • 9.3.2.2.1. By Technology
      • 9.3.2.2.2. By Application
      • 9.3.2.2.3. By Cancer Type
  • 9.3.3. South Africa Next Generation Cancer Diagnostics Market Outlook
    • 9.3.3.1. Market Size & Forecast
      • 9.3.3.1.1. By Value
    • 9.3.3.2. Market Share & Forecast
      • 9.3.3.2.1. By Technology
      • 9.3.3.2.2. By Application
      • 9.3.3.2.3. By Cancer Type

10. South America Next Generation Cancer Diagnostics Market Outlook

• 10.1. Market Size & Forecast
  • 10.1.1. By Value
• 10.2. Market Share & Forecast
  • 10.2.1. By Technology
  • 10.2.2. By Application
  • 10.2.3. By Cancer Type
  • 10.2.4. By Country
• 10.3. South America: Country Analysis
  • 10.3.1. Brazil Next Generation Cancer Diagnostics Market Outlook
    • 10.3.1.1. Market Size & Forecast
      • 10.3.1.1.1. By Value
    • 10.3.1.2. Market Share & Forecast
      • 10.3.1.2.1. By Technology
      • 10.3.1.2.2. By Application
      • 10.3.1.2.3. By Cancer Type
  • 10.3.2. Colombia Next Generation Cancer Diagnostics Market Outlook
    • 10.3.2.1. Market Size & Forecast
      • 10.3.2.1.1. By Value
    • 10.3.2.2. Market Share & Forecast
      • 10.3.2.2.1. By Technology
      • 10.3.2.2.2. By Application
      • 10.3.2.2.3. By Cancer Type
  • 10.3.3. Argentina Next Generation Cancer Diagnostics Market Outlook
    • 10.3.3.1. Market Size & Forecast
      • 10.3.3.1.1. By Value
    • 10.3.3.2. Market Share & Forecast
      • 10.3.3.2.1. By Technology
      • 10.3.3.2.2. By Application
      • 10.3.3.2.3. By Cancer Type

11. Market Dynamics

• 11.1. Drivers
• 11.2. Challenges

12. Market Trends & Developments

• 12.1. Merger & Acquisition (If Any)
• 12.2. Product Launches (If Any)
• 12.3. Recent Developments

13. Global Next Generation Cancer Diagnostics Market: SWOT Analysis

14. Porter's Five Forces Analysis

• 14.1. Competition in the Industry
• 14.2. Potential of New Entrants
• 14.3. Power of Suppliers
• 14.4. Power of Customers
• 14.5. Threat of Substitute Products

15. Competitive Landscape

• 15.1. GE HealthCare
  • 15.1.1. Business Overview
  • 15.1.2. Products & Services
  • 15.1.3. Recent Developments
  • 15.1.4. Key Personnel
  • 15.1.5. SWOT Analysis
• 15.2. Janssen Pharmaceuticals, Inc.
• 15.3. Illumina, Inc.
• 15.4. Novartis AG
• 15.5. F. Hoffmann-La Roche Ltd
• 15.6. Koninklijke Philips N.V.
• 15.7. QIAGEN
• 15.8. Agilent Technologies, Inc.
• 15.9. Abbott Laboratories Inc.
• 15.10. Thermo Fisher Scientific Inc

16. Strategic Recommendations

17. About Us & Disclaimer